As shown in Figure 3I, ETRQβ-002 treatment effectively reduced mRNA expression of classical proinflammatory cytokines including IL-1β, IL-6, monocyte chemoattractant protein 1, and tumor necrosis factor α, some of which were significantly increased in patients with PAH (23, 24). This evidence concerns the gene CCL2 and pulmonary arterial hypertension.